This is just news from the company - so we’ll see how it does in the real world with data from third parties:
A novel antipsychotic that treats predominant persistent negative symptoms in schizophrenia and improves overall function is significantly more effective than standard antipsychotic therapy and is well tolerated, new phase 3 trial results indicate.
“What’s important is that cariprazine was significantly more effective than risperidone [Risperdal, Janssen Pharmaceuticals, Inc] at not only improving symptoms but also the functionality of patients,” George Nemeth, MD, PhD, chief medical officer, Gedeon Richter, Budapest, Hungary, told Medscape Medical News.
“The drug has a pending New Drug Application as of March 2015 for bipolar I and schizophrenia, with a decision expected by the FDA in the second quarter of 2015.”